UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1168-1174

2010

Volltextzugriff (PDF)

VP11.12: Fetal giant intra‐ and extra‐abdominal lymphangioma is a challenge of counselling

Ultrasound in obstetrics & gynecology, 2021-10, Vol.58 (S1), p.140-140

2021

Volltextzugriff (PDF)

Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States

Current oncology (Toronto), 2023-02, Vol.30 (2), p.1869-1881

2023

Volltextzugriff (PDF)

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

Journal of Gastric Cancer, 2017, 17(2), , pp.132-144

2017

Volltextzugriff (PDF)

Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016-04, Vol.19 (2), p.607-615

2016

Volltextzugriff (PDF)

What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures?

Value in health, 2007-11, Vol.10, p.S94-S105

2007

Volltextzugriff (PDF)

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016-07, Vol.19 (3), p.927-938

2016

Volltextzugriff (PDF)

Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-09, Vol.21 (5), p.738-744

2018

Volltextzugriff (PDF)

Qualitative Development and Content Validity of the Non–small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument

Clinical therapeutics, 2016-04, Vol.38 (4), p.794-810

2016

Volltextzugriff (PDF)

Non–Small Cell Lung Cancer Symptom Assessment Questionnaire: Psychometric Performance and Regulatory Qualification of a Novel Patient-Reported Symptom Measure

Current therapeutic research, 2021-01, Vol.95, p.100642-100642, Article 100642

2021

Volltextzugriff (PDF)

Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-09, Vol.21 (5), p.831-844

2018

Volltextzugriff (PDF)

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

The lancet oncology, 2012-03, Vol.13 (3), p.292-299

2012

Volltextzugriff (PDF)

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

BMC urology, 2020-11, Vol.20 (1), p.181-181, Article 181

2020

Volltextzugriff (PDF)

Recommendations for including multiple symptoms as endpoints in cancer clinical trials

Cancer, 2013-01, Vol.119 (2), p.411-420

2013

Volltextzugriff (PDF)

Health-Related Quality-of-Life Parameters as Independent Prognostic Factors in Advanced or Metastatic Bladder Cancer

Journal of clinical oncology, 2003-02, Vol.21 (4), p.673-678

2003

Volltextzugriff (PDF)

Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database

Journal of Gastric Cancer, 2015, 15(2), , pp.87-104

2015

Volltextzugriff (PDF)

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

Cancer Research and Treatment, 2017, 49(3), , pp.578-587

2017

Volltextzugriff (PDF)

Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.e1538-e1547

2021

Volltextzugriff (PDF)

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

The Lancet (British edition), 2017-11, Vol.390 (10109), p.2266-2277

2017

Volltextzugriff (PDF)

Hepatocellular carcinoma after prior sorafenib treatment: Incidence, healthcare utilisation and costs from German statutory health insurance claims data

Health economics review, 2018-08, Vol.8 (18), p.1-10, Article 18

2018

Volltextzugriff (PDF)

A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer

Cancer management and research, 2014-01, Vol.6 (default), p.437-449

2014

Volltextzugriff (PDF)

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials

European journal of cancer (1990), 2019-01, Vol.107, p.115-123

2019

Volltextzugriff (PDF)

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

Journal of thoracic oncology, 2009-11, Vol.4 (11), p.1404-1414

2009

Volltextzugriff (PDF)

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer

Lung cancer (Amsterdam, Netherlands), 2012-10, Vol.78 (1), p.63-69

2012

Volltextzugriff (PDF)

1 – 25 von 273

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(227)
Mit Volltextzugriff
(227)

Publikationsform

Artikel
(267)
Tagungsberichte
(6)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(115)
Life Sciences & Biomedicine
(84)
Humans
(74)
Female
(46)
Male
(44)
Oncology
(44)
Middle Aged
(40)
Aged
(35)
Adult
(32)
Quality Of Life
(25)
Treatment Outcome
(23)
Physical Sciences
(22)
Biological And Medical Sciences
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Gastric Cancer
(18)
Patients
(18)
Medical Sciences
(17)
Social Sciences
(17)
Aged, 80 And Over
(15)
Chemistry
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

VP11.12: Fetal giant intra‐ and extra‐abdominal lymphangioma is a challenge of counselling

Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data

What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures?

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S

Qualitative Development and Content Validity of the Non–small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument

Non–Small Cell Lung Cancer Symptom Assessment Questionnaire: Psychometric Performance and Regulatory Qualification of a Novel Patient-Reported Symptom Measure

Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Recommendations for including multiple symptoms as endpoints in cancer clinical trials

Health-Related Quality-of-Life Parameters as Independent Prognostic Factors in Advanced or Metastatic Bladder Cancer

Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea

Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Hepatocellular carcinoma after prior sorafenib treatment: Incidence, healthcare utilisation and costs from German statutory health insurance claims data

A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer

Suchergebnisse filtern